JNJ-90301900 (NBTXR3)

NBTXR3 · Johnson & Johnson Enterprise Innovation Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-90301900 (NBTXR3), covering 2026-03-13 to 2026-03-13. Get the full timeline:

Most recent: Clinical Trial Update: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC [Phase 3]